Exploring new strategy in erenumab therapy for migraine patients
- 1 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 41 (SUPPL 2), 507-508
- https://doi.org/10.1007/s10072-020-04678-x
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment terminationThe Journal of Headache and Pain, 2019
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine preventionThe Journal of Headache and Pain, 2019
- A Controlled Trial of Erenumab for Episodic MigraineThe New England Journal of Medicine, 2017